Seeking Alpha
Long/short equity, dividend growth investing, growth, long-term horizon
Profile| Send Message|
( followers)  

A Dividend Contender is defined as a company that has increased its dividend for a minimum of 10 - 24 straight years. Teva Pharmaceutical (NYSE:TEVA) is a Dividend Contender that has raised its dividend every year for 13 consecutive years. The complete Dividend Contenders list is compiled courtesy of David Fish. (Open as an excel spreadsheet and look at the tabs on the bottom to find the Dividend Contender list).

About Teva Pharmaceutical : from its website

Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011.

Teva Pharmaceutical : A Dividend Contender with 13 Consecutive Years of Dividend Increases

Since dividends are paid out of earnings, a clear perspective of a company's historical earnings growth record is a vital component of a dividend investor's prudent due diligence process. The following graph plots Teva Pharmaceutical's earnings per share since 1998. A quick glance to the right of the graph shows that Teva Pharmaceutical has increased earnings at a compounded rate of 23.1% (see purple circle on graph) per annum.

(Click charts to enlarge)

Dividend Contenders 10-24 Straight Years of Dividend Increases

With interest rates hovering near all-time lows, investors seeking income are faced with very limited choices. The traditional high yields available from bonds and other fixed income vehicles are no longer available to meet the goals of retirees needing income to live off. Moreover, it is almost a certainty that today's low yields are not adequate enough to fight inflation. Consequently, there is a growing investor interest in dividend-paying common stocks, especially those that have a long record of increasing their dividends every year.

Earnings Determine Market Price and Dividend Income: The following earnings and price correlated F.A.S.T. Graphs™ clearly illustrates the importance of earnings to both price movement and dividend income. The earnings growth rate line or True Worth ™ line (orange line with white triangles) is correlated with the historical stock price line. On graph after graph the lines will move in tandem. If the stock price strays away from the earnings line (over or under), inevitably it will come back to earnings.

Since dividends are paid out of earnings, and therefore represent additional return on top of what the market capitalizes earnings at, they are depicted by the light blue shaded area and stacked on top of the earnings line. Therefore, a quick visual of these two important components is simultaneously revealed: The additional return that dividend paying stocks provide, plus the percentage of earnings paid to shareholders as dividends (payout ratio).

Performance Table: Capital Appreciation and Dividend Income Teva Pharmaceutical

The associated performance results with the earnings and price correlated graph, validates the above discussion regarding the two components of total return: Capital appreciation and dividend income. Dividends are included in the total return calculation and are assumed paid, but not reinvested.

When presented separately like this, the additional rate of return a dividend paying stock produces for shareholders becomes undeniably evident. In addition to the 15.4% capital appreciation (Closing Annualized ROR), long-term shareholders of Teva Pharmaceutical would have received an additional $72,823.67 in dividends that increased their total return from 15.4% to 16.1% per annum.

(Note: Since this is a Dividend Contender it has raised its dividend every year for at least 10-24 years, therefore, negative dividend growth rates shown, if any, will be attributed to special additional dividends paid in excess of the company's regularly reported dividend rate)

The following graph plots the historically normal PE ratio (the dark blue line) correlated with 10-year Treasury note interest. Notice that the current price earnings ratio on this quality company is as low as it has been since 1998.

A further indication of valuation can be seen by examining a company's current price-to-sales ratio relative to its historical price-to-sales ratio. The current price-to-sales ratio for Teva Pharmaceutical is 2.17, which is historically low.

Looking to the Future

Extensive research has provided a preponderance of conclusive evidence that future long-term returns, and the dividend and its growth rate are a function of two critical determinants:

  1. The rate of change (growth rate) of the company's earnings
  2. The price or valuation you pay to buy those earnings

Therefore, forecasting future earnings growth, bought at sound valuations, is the key to safe, sound and profitable performance.

Therefore, it logically follows that measuring performance without simultaneously measuring valuation is a job half done. At its current price, which is attractively aligned with its True Worth™ valuation, Teva Pharmaceutical represents a potential opportunity to invest in a Dividend Contender at a reasonable price. The important factor is that Teva Pharmaceutical has real assets and cash flow underpinning its stock price. This solid economic foundation offers shareholders the potential for both a strong margin of safety and an opportunity for an increasing dividend income stream and potentially attractive future returns.

The Estimated Earnings and Return Calculator Tool is a simple yet powerful resource that empowers the user to calculate and run various investing scenarios that generate precise rate of return potentialities. Thinking the investment through to its logical conclusion is an important component toward making sound and prudent commonsense investing decisions.

The consensus of 22 leading analysts reporting to Capital IQ forecast Teva Pharmaceutical's long-term earnings growth at 9.4%. Teva Pharmaceutical has low long-term debt at 31% of capital. Teva Pharmaceutical is currently trading at a P/E of 9.9, which is outside the value corridor (defined by the five orange lines) of a maximum P/E of 18. If the earnings materialize as forecast, Teva Pharmaceutical's True Worth valuation would be $129.13 at the end of 2017, which would be a 20.8% annual rate of return from the current price, including assumed dividends.

Earnings Yield Estimates

Discounted Future Cash Flows: All companies derive their value from the future cash flows (earnings) they are capable of generating for their stakeholders over time. Therefore, because Earnings Determine Market Price and dividend income in the long run, we expect the future earnings of a company to justify the price we pay.

Since all investments potentially compete with all other investments, it is useful to compare investing in any prospective company to that of a comparable investment in low-risk Treasury bonds. Comparing an investment in Teva Pharmaceutical to an equal investment in 10-year Treasury bonds illustrates that Teva Pharmaceutical's expected earnings would be 9.5 times that of the 10-Year T-Bond Interest. (See EYE chart below). This is the essence of the importance of proper valuation as a critical investing component.

Summary & Conclusions

This report presents essential "fundamentals at a glance" on Dividend Contender Teva Pharmaceutical, illustrating the past and present valuation based on earnings achievements as reported. Future forecasts for earnings growth are based on the consensus of leading analysts. Although with just a quick glance you can know a lot about the company, it's imperative that the reader conduct his or her own due diligence in order to validate whether the consensus estimates seem reasonable or not.

Disclosure: I am long TEVA.

Disclaimer: The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients. Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted. The information in this document is believed to be accurate, but under no circumstances should a person act upon the information contained within. We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation.

Source: Teva Pharmaceutical: Dividends, Earnings And Valuation Analysis